

Lupin inks licensing agreement with Alvion for cardiometabolic drugs in SE Asia

05 April 2022 | News

The company will play a significant role in improving the quality of healthcare and access to medicines



Lupin has entered into a licensing agreement with Alvion Pharmaceuticals to commercialise medicines for cardiometabolic diseases in the South East Asia region. By commercialising cardiometabolic drugs in the South East Asian region, Lupin will play a significant role in improving the quality of healthcare and access to medicines.

Gabriel Georgy, Regional Head South East Asia, Lupin said, “Forming a long-term collaboration with Alvion to launch a range of therapies will allow Lupin to expand its footprint across South East Asia with quality cost-effective alternatives for patients and the healthcare system. Both companies have a solid track record of developing and launching products and this agreement will further cement Lupin as a formidable pharmaceutical company in the region.”

John Bouros, CEO, Alvion said, “Being a leader in value-added medicines, Alvion shall support Lupin’s activities aiming to position both companies at the forefront for both molecules.”